pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN, Rooney C, Griffin N, Roudier M, Young LA, Garcia-Trinidad A, Hughes GD, Whiteaker JR, Wilson Z, Odedra R, Zhao L, Ivey RG, Howat WJ, Harrington EA, Barrett JC, Ramos-Montoya A, Lau A, Paulovich AG, Cadogan EB, Pierce AJ.
Jones GN, et al. Among authors: young la.
Br J Cancer. 2018 Nov;119(10):1233-1243. doi: 10.1038/s41416-018-0286-4. Epub 2018 Nov 2.
Br J Cancer. 2018.
PMID: 30385821
Free PMC article.